Product information and disease descriptionPlace of product in therapyDisease description
Long-term morbidity
5 evidence topics · 7 sources
Long-term disability and loss of ambulation
“The pooled fraction of nonambulatory patients was 8.2% (95% CI, 5.7% to 11.6%) and, overall, 47.1% (95% CI, 39.5% to 54.9%) of CIDP patients had a good outcome without disability.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Use of mobility aids
“Overall, 47.3% of patients with CIDP (ranging from 41.7% in Japan and 50.0% in China) were recorded to use mobility aids at the time of data collection. Across all regions, a cane/walking stick was used by 35.3% of patients, followed by the wheeled walker (8.0%), walking frame, and/or manual wheelchair (both 4.9%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment delay and accumulation of irreversible disability
“Prolongation of time until start of therapy was associated with an increased burden of long-term disability.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment initiation within 1 year of onset was significantly associated with lesser post‐treatment disability and greater amplitude of treatment response, in each cohort separately, and in the combined cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Early treatment initiation is a key modifiable determinant of favorable long‐term disability in CIDP. These findings underscore the importance of timely diagnosis and prompt treatment to prevent irreversible axonal damage.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients who started their initial treatment later experienced a worsening disease course, as reflected by a significant deterioration in their Inflammatory Neuropathy Cause and Treatment (INCAT) leg disability score.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Refractory disease despite standard-of-care therapy
“Overall, 110 (56%) patients responded to their first therapy and were thus assigned to the status SOC-responder” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“76 (39%) patients did not respond to their first therapy and were assigned to the status SOC-refractory” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“SOC-refractory patients had worse clinical outcomes than SOC-responders. Associated factors for SOC-refractory status included the presence of fatigue as a symptom and alcohol dependence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cancer risk compared with the general population
“The observed number of cancer diagnoses corresponded to an incidence rate of 5.63%, with a standardized incidence ratio (SIR) of 2.83 (95% confidence interval [CI]: 1.89–4.39) compared to the expected cancer incidence rate of 2.00%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote